OM MUC 1

Drug Profile

OM MUC 1

Alternative Names: Oxidised-mannan MUC1 vaccine

Latest Information Update: 04 Nov 2015

Price : $50

At a glance

  • Originator Austin Research Institute
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Breast cancer

Most Recent Events

  • 10 Oct 2015 Efficacy, immunogenicity and adverse events data from the phase IIb/III IFCM-9 trial in Breast cancer (Adjuvant therapy, Early-stage disease, Second-line therapy or greater, Prevention) released by Ascend Biopharmaceuticals (3151181; ISRCTN71711835)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top